Answers are grounded in this paper and cite their sources.
Phase 3 trial demonstrates efficacy and safety of onabotulinumtoxinA for masseter muscle prominence, suggesting significant patient-reported benefits.
Background Masseter muscle prominence (MMP) may be aesthetically bothersome to some individuals, leading them to seek treatment for a slimmer lower face. Objectives Evaluate the safety and efficacy of onabotulinumtoxinA for treatment of MMP, including patient-reported outcomes (PROs). Methods This was a prospective, multicenter trial including a randomized, double-blind, placebo-controlled period (days 1−180) in which adults rated Grade 4 or 5 (Marked/Very marked) on the investigator-assessed MMP Scale (MMPS) were randomized to onabotulinumtoxinA 72 U or placebo. Efficacy endpoints were assessed at day 90. The primary endpoint was ≥2-grade improvement from baseline on the investigator-assessed MMPS. Secondary endpoints included achieving Grade ≤3 on the MMPS and subject-assessed MMPS-Participant (MMPS-P), ≥2-grade improvement on the subject-assessed MMPS-P, and change from baseline in lower facial width. Outcomes were assessed using validated measures. Adverse events (AEs) were monitored. Results Of 376 enrolled subjects (onabotulinumtoxinA, n=283; placebo, n=93), 310 (82.4%) completed the study. At day 90, a greater proportion of onabotulinumtoxinA-treated subjects vs placebo achieved MMPS ≥2-grade improvement (51.2% vs 2.2%, P<.0001), and more onabotulinumtoxinA-treated subjects vs placebo achieved the secondary endpoints (all P<.0001), with mean lower facial width reduction of −5.24 mm for onabotulinumtoxinA vs −0.04 mm for placebo (P<.0001). Subjects reported benefits for onabotulinumtoxinA vs placebo in self-perceived change in MMP, treatment satisfaction, and psychosocial impact. Improvements were sustained through day 180. Most AEs were mild, nonserious, and resolved. Conclusions OnabotulinumtoxinA effectively reduced the appearance of MMP and improved PROs, with effects lasting up to 6 months and a favorable safety profile.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: